Nitric oxide synthase gene and protein expression are upregulated by Bacille Calmette-Guerin in the rat bladder

被引:12
作者
Oh, BR
Nakajima, K
Ahn, KY
Ryu, SB
Park, YI
Dahiya, R
机构
[1] Vet Adm Med Ctr, Urol Res Ctr 112F, Dept Urol, San Francisco, CA 94121 USA
[2] Univ Calif San Francisco, San Francisco, CA 94121 USA
[3] Chonnam Natl Univ, Sch Med, Dept Urol & Anat, Kwangju 501190, South Korea
[4] Toho Univ, Dept Urol, Tokyo, Japan
关键词
BCG; bladder; iNOS; eNOS; nNOS;
D O I
10.1159/000052466
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: We hypothesize that Bacille Calmette-Guerin (BCG) may act through the regulation of various isoforms of nitric oxide synthase (NOS) [inducible (iNOS), endothelial (eNOS), and neuronal (nNOS)] genes and protein expression in rat bladder. Methods: Adult female Sprague-Dawley rats (200-250 g)were injected transurethrally with BCG (22 rats) and phosphate-buffered saline (22 control rats), and after 2, 4, 6, and 12 h, and 1, 2, 3, 5, 7, 10, and 14 days, the bladders were harvested. Normal and BCG-treated rat bladders were analyzed for mRNA expression for iNOS, eNOS, and nNOS by reverse-transcriptase polymerase chain reaction. Protein expression was determined by Western blotting and immunohistochemistry. Results: mRNA expression for iNOS was induced after 2 h of BCG injection in the rat bladder. Gene expression for iNOS was highest at 6 h to 1 day followed by decreased expression, reaching its lowest level at 5 days. eNOS mRNA expression was detected in control bladders, but its level was higher in the BCG-treated animals, nNOS mRNA expression was present in all samples, bur did not change after BCG treatment. Western blotting confirmed these findings. Immunohistochemistry analysis demonstrated that eNOS was present mainly in endothelium, while iNOS was detected in stroma and nNOS in epithelium and smooth muscle of the rat bladder. Conclusion: The present study demonstrates, for the first time, that BCG treatment up-regulates gene and protein expression of iNOS and eNOS in normal rat bladders, suggesting that BCG action may be mediated through NOS pathways. Copyright (C) 2001 S. Karger AG, Basel.
引用
收藏
页码:349 / 356
页数:8
相关论文
共 34 条
  • [1] BCG immunotherapy of bladder cancer: 20 years on
    Alexandroff, AB
    Jackson, AM
    O'Donnell, MA
    James, K
    [J]. LANCET, 1999, 353 (9165) : 1689 - 1694
  • [2] BETTEX-GALLAND M, 1991, European Urology, V19, P171
  • [3] EFFECTS OF LOCAL BACILLUS CALMETTE-GUERIN THERAPY IN PATIENTS WITH BLADDER-CARCINOMA ON IMMUNOCOMPETENT CELLS OF THE BLADDER WALL
    BOHLE, A
    GERDES, J
    ULMER, AJ
    HOFSTETTER, AG
    FLAD, HD
    [J]. JOURNAL OF UROLOGY, 1990, 144 (01) : 53 - 58
  • [4] ELEVATIONS OF CYTOKINES INTERLEUKIN-1, INTERLEUKIN-2 AND TUMOR-NECROSIS-FACTOR IN THE URINE OF PATIENTS AFTER INTRAVESICAL BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY
    BOHLE, A
    NOWC, C
    ULMER, AJ
    MUSEHOLD, J
    GERDES, J
    HOFSTETTER, AG
    FLAD, HD
    [J]. JOURNAL OF UROLOGY, 1990, 144 (01) : 59 - 64
  • [5] THE IMPORTANCE OF A LIPOPOLYSACCHARIDE-INITIATED, CYTOKINE-MEDIATED HOST-DEFENSE MECHANISM IN MICE AGAINST EXTRAINTESTINALLY INVASIVE ESCHERICHIA-COLI
    CROSS, A
    ASHER, L
    SEGUIN, M
    YUAN, L
    KELLY, N
    HAMMACK, C
    SADOFF, J
    GERNSKI, P
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (02) : 676 - 686
  • [6] Dahiya R, 1996, Urol Oncol, V2, P52, DOI 10.1016/S1078-1439(96)00048-8
  • [7] Dahiya R, 1995, Urol Oncol, V1, P42, DOI 10.1016/1078-1439(95)00001-X
  • [8] DAHIYA R, 1993, CANCER RES, V53, P1437
  • [9] INHIBITION OF TUMORIGENIC POTENTIAL AND PROSTATE-SPECIFIC ANTIGEN EXPRESSION IN LNCAP HUMAN PROSTATE-CANCER CELL-LINE BY 13-CIS-RETINOIC ACID
    DAHIYA, R
    PARK, HD
    CUSICK, J
    VESSELLA, RL
    FOURNIER, G
    NARAYAN, P
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1994, 59 (01) : 126 - 132
  • [10] INDUCTION OF URINARY INTERLEUKIN-1 (IL-1), IL-2, IL-6, AND TUMOR-NECROSIS-FACTOR DURING INTRAVESICAL IMMUNOTHERAPY WITH BACILLUS CALMETTE-GUERIN IN SUPERFICIAL BLADDER-CANCER
    DEBOER, EC
    DEJONG, WH
    STEERENBERG, PA
    AARDEN, LA
    TETTEROO, E
    DEGROOT, ER
    VANDERMEIJDEN, APM
    VEGT, PDJ
    DEBRUYNE, FMJ
    RUITENBERG, EJ
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 1992, 34 (05) : 306 - 312